Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00833690 · ClinicalTrials.gov registry record · Phase 2
Safety of Urate Elevation in Parkinson's Disease
A Phase 2 study, sponsored by The Parkinson Study Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
NCT00833690 is a Phase 2 study that has completed, run by The Parkinson Study Group. The registered enrollment target is 75 participants.
The verdict
NCT00833690, a Phase 2 study, has completed, sponsored by The Parkinson Study Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and tolerability of inosine and its ability to raise urate levels in blood and cerebral spinal fluid in individuals with early Parkinson disease. This will determine whether it is appropriate to proceed with a larger study of inosine's ability to modify the rate of disability progression in PD.
Interventions
- DRUG Placebo
- DRUG inosine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2009-06 |
| Est. Completion | 2012-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00833690
The ClinicalTrials.gov registry entry for NCT00833690 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Parkinson Study Group, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00833690 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00833690 about?
NCT00833690 is a clinical study titled "Safety of Urate Elevation in Parkinson's Disease". The purpose of this study is to determine the safety and tolerability of inosine and its ability to raise urate levels in blood and cerebral spinal fluid in individuals with early Parkinson disease. This will determine whether it is appropriate to proceed with a larger study of inosine's ability to ...
What is the current status of trial NCT00833690?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2009-06. Estimated completion is 2012-12.
What interventions are being tested in trial NCT00833690?
The interventions under investigation include: Placebo (DRUG), inosine (DRUG).
Who is sponsoring clinical trial NCT00833690?
This trial is sponsored by The Parkinson Study Group, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.